Ann Marie O'Neill/aum.edu
May 20, 2026, 08:03
Ann Marie O’Neill: Help Us Improve Information for DOAC Medicines
Ann Marie O’Neill, Operations Manager at The Meath Foundation , Thrombosis Patient Advocate, shared a post on LinkedIn:
“We are inviting people who take Direct Oral Anticoagulant Medication (DOAC) eg. Apixaban (Eliquis) Rivaroxaban (Xaralto) or Dabigatran (Pradaxa) after experiencing a blood clot, to join a small focus group to help us improve our Patient information booklet.
If you are a VTE Health Care Professional, please share with your relevant Patients.
The more the merrier.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:12Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery